Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

Genetic Cohort Participants
Enrollment Goal: 600

Genetic Registry Participants
Enrollment Goal: ~600

De Novo PD Participants
Enrollment: 423

Control Participants
Enrollment: 196

Subjects with SWEDD
Enrollment: 64

Prodromal Participants
Enrollment: 65

Last Update: July 11, 2016


More about study cohorts >

Landmark Study to Find Biomarkers

Biomarkers are the critical missing links in the search for better Parkinson’s disease treatments.

The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate people with Parkinson’s disease and those at greater risk of developing the disease, as well as healthy controls. The goal is to identify one or more biomarkers of Parkinson’s disease progression.   This longitudinal study, following over 1,000 participants for up to 8 years, is taking place at 33 clinical sites in the United States, Europe, Israel and Australia.

Critical data and biospecimens are currently available for the research community.

The comprehensive PPMI database and biorepository, includes:

>  Clinical and behavioral assessments
>  Imaging data
>  Biospecimens: cerebral spinal fluid, DNA, RNA, plasma, serum, urine and cell lines
PPMI is made possible by the concerted efforts of a number of collaborators and sponsored by The Michael J. Fox Foundation for Parkinson’s Research.


The Michael J. Fox Foundation Announces $25,000 PPMI Data Challenge to Advance Parkinson’s Understanding and Study Design

Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer fundamental questions about Parkinson’s that limit our understanding and slow drug testing. The PPMI Data Challenge offers $25,000 each to two teams that develop models to answer either: • What factors at baseline predict […]

2016 PPMI Annual Meeting held in New York City

The 2016 PPMI annual meeting took place on May 4-5 in New York City.  The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners.  During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]

PPMI Q1 2016 Study Update call

On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.

Researchers identify biomarker for early cognitive decline in Parkinson’s disease patients using PPMI data

Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson’s Disease indicates that lower concentrations of α-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.

Dr. Omar El-Agnaf to use PPMI biospecimens for validation of cerebral spinal fluid α-synuclein species as surrogate biomarkers for Parkinson’s disease

We are excited to announce another recent approval by our Biospecimen Review Committee. Dr. Omar El-Agnaf, Professor at Hamad Bin Khalifa University in Doha, Qatar, will be using PPMI biospecimens for a project entitled: Validation of CSF α-synuclein species as surrogate biomarkers for Parkinson’s disease. Dr. El-Agnaf has recently reported higher levels of the oligomeric […]

Learn More